Navigation Links
U.S. Expects 160 Million Doses of Swine Flu Vaccine by October
Date:7/23/2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... Our Lady of Lourdes Health Care Services ... has agreed to pay the United States $7.95 million ... Justice Department announced today. The two hospitals are Our ... and Lourdes Medical Center of Burlington County (LMC) in ... a suit brought by a whistleblower, Tony Kite, in ...
(Date:12/15/2009)... associated with lower dementia risk, research finds , , TUESDAY, ... leptin, a hormone that regulates appetite, may guard against ... or 15 years this may be one of many ... Alzheimer,s disease," said senior study author Dr. Sudha Seshadri, ... of Medicine. "Or it may be one of many ...
(Date:12/15/2009)... sobering statistics concerning the parallel rise in diabetes and obesity rates ... of combating this trend afflicting their workforce. , ... ... climbing across America due in large part to the alarming parallel ... has stated that the rate of diabetes could be cut in ...
(Date:12/15/2009)... Dec. 15 Knowledge ... the pharmaceutical and bio-tech research market with ... Over the past 11 years CMR has ... Consulting Network (PCN®), which now includes 70,000 ... both primary care and hard-to-reach specialties. ...
(Date:12/15/2009)... -- Patient advocate Betsy McCaughey, ... Congress that, "it doesn,t matter whether there,s a public ... a public option - give government authority over how ... a new social agenda by shifting billions of dollars ... arriving immigrants, and local politicians." ,, Betsy ...
Breaking Medicine News(10 mins):Health News:Parent Company of Two New Jersey Hospitals to Pay U.S. $7.95 Million to Settle False Claims Act Allegations 2Health News:Fat Hormone May Protect Against Alzheimer's 2Health News:Fat Hormone May Protect Against Alzheimer's 3Health News:TrekDesk: A Potentially Positive Impact on Diabetes & Obesity 2Health News:TrekDesk: A Potentially Positive Impact on Diabetes & Obesity 3Health News:Knowledge Networks Expands in Pharma Research With Acquisition of CMR 2
... A just-published research study by Dr. R Preston ... that astaxanthin, a relatively //unknown carotenoid found in ... for a new therapy to treat cardiovascular disease ... models. ,Combined with published proof-of-concept, pre-clinical and ...
... no one big way to reduce your risk for breast ... reports //the January 2007 issue of Harvard Women’s Health Watch. ... , Weight gain: Studies show that weight gain is ... is estrogen, which is believed to promote the development of ...
... can make a dramatic difference in the management of patients ... patients, a new study finds. // ,The study, ... of 35% of patients, said Philip W.P. Bearcroft, MD, of ... but more significant is the fact that before an MRI ...
... as well as widening the scope of its potential ... an instructional course at the recent American Academy of ... “LASIK in Eyes Following Previous Surgery: A Practical Approach ... Dr. Kanellopoulous, who was joined by Gregory Pamel, MD ...
... Meningitis scare has kept 20,000 children in three communities ... were closed on Thursday and Friday.// ,On ... Meningitis is the condition in which membranes protecting the ... the brain. Mycoplasma occasionally causes these neurological complications. ...
... posting of home video clips. All net lovers acclaimed it ... have put this novel invention to all possible uses. ... the website to get across health advice to patients. Last ... inhaler properly was launched in the website. ,Builth ...
Other Medicine News:Health News:Study Finds Astaxanthin Is Potent Inhibitor of Oxidation in Cell Membrane Model 2Health News:Study Finds Astaxanthin Is Potent Inhibitor of Oxidation in Cell Membrane Model 3Health News:Technology Making LASIK Safer for Those Who Have Had Previous Eye Surgery 2
(Date:12/15/2009)... Dec. 15 Today,s New ... "Plan for Kidney Drugs Spurs Division," illustrates an ... in kidney patients continuing to be deprived of ... Medicare program limit. ,, As Congress is poised ... preserve the lives of transplant kidney recipients, behind-the-scenes ...
(Date:12/15/2009)... YORK, Dec. 15 ,, Reportlinker.com ... is available in its catalogue: ,, ... Market Forecasts to 2015 ,, ... Pipeline Analysis and Market Forecasts to 2015 ... industry analysis specialist,s new report, "Hepatitis B ...
(Date:12/15/2009)... Dec. 15 Waters Corporation (NYSE: ... Vision Publisher(TM) (v.7.1 SR4), an electronic laboratory notebook ... (SDMS), a secure electronic repository that stores and ... centralized database and is used to boost efficiency ... with the SAFE-BioPharma digital identity and signature standard. ...
Breaking Medicine Technology:AST Concerned That Kidney Transplant Patients May Suffer Politics As Usual in Capitol Hill Health Care Reform Debate 2Reportlinker Adds Hepatitis B Vaccines - Pipeline Analysis and Market Forecasts to 2015 2Reportlinker Adds Hepatitis B Vaccines - Pipeline Analysis and Market Forecasts to 2015 3Reportlinker Adds Hepatitis B Vaccines - Pipeline Analysis and Market Forecasts to 2015 4Reportlinker Adds Hepatitis B Vaccines - Pipeline Analysis and Market Forecasts to 2015 5Reportlinker Adds Hepatitis B Vaccines - Pipeline Analysis and Market Forecasts to 2015 6Reportlinker Adds Hepatitis B Vaccines - Pipeline Analysis and Market Forecasts to 2015 7Waters SDMS Vision Publisher Now Certified Compliant with SAFE-BioPharma Digital Standard 2Waters SDMS Vision Publisher Now Certified Compliant with SAFE-BioPharma Digital Standard 3Waters SDMS Vision Publisher Now Certified Compliant with SAFE-BioPharma Digital Standard 4Waters SDMS Vision Publisher Now Certified Compliant with SAFE-BioPharma Digital Standard 5Waters SDMS Vision Publisher Now Certified Compliant with SAFE-BioPharma Digital Standard 6Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 6455 1Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 6455 2Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 6455 3Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 6455 4Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 6455 5Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 6455 6Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 6455 7Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 6455 8Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 6455 9Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 6455 10QlikTech Wins Healthcare IT Innovation 26amp 3B 238482 3B Award 61914 1QlikTech Wins Healthcare IT Innovation 26amp 3B 238482 3B Award 61914 2QlikTech Wins Healthcare IT Innovation 26amp 3B 238482 3B Award 61914 3QlikTech Wins Healthcare IT Innovation 26amp 3B 238482 3B Award 61914 4Tis the Season to Eat and Eat More 21 61910 1Tis the Season to Eat and Eat More 21 61910 2
... Combination Clinical Trials ... SOUTH SAN FRANCISCO, Calif., June 16 Sunesis,Pharmaceuticals, Inc. (Nasdaq: ... the company,s lead drug candidate, voreloxin (formerly,SNS-595), including updated results ... single agent in relapsed or refractory patients with acute,myeloid leukemia ...
... 16 ADVENTRX Pharmaceuticals,Inc. (Amex: ANX ) ... survival,from its Phase 2b clinical trial of CoFactor ... survival results in this,study have been revised upwards ... day improvement in overall survival,compared to the leucovorin/5-FU ...
Other Medicine Technology:Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association 2Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association 3Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association 4Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association 5Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association 6ADVENTRX Announces CoFactor(R) Phase 2b Clinical Trial Overall Survival Results 2ADVENTRX Announces CoFactor(R) Phase 2b Clinical Trial Overall Survival Results 3
... new biological material produced from ... implant, lyoplant can absorb in ... implant material with the recipient's ... minimizes suture channels, resulting in ...
Elmed electrosurgical systems for major surgery....
Adson bipolar forceps, 12 cm, straight....
Straight, blunt and pointed tips....
Medicine Products: